Our advertisers

CliniMed Limited
University of Plymouth
Nutricia Ltd
Solus Medical Limited
Milton Pharmaceuticals Co UK Ltd
Armstrong Medical
Central Medical Supplies Ltd
vCreate Neonatal
ParAid
Medela AG
SBK (UK) Ltd
Inspiration Healthcare
Vygon (UK) Ltd
Baxter Healthcare Ltd
Intersurgical Ltd
The Brazelton Centre UK

 

 

Volume 15/Issue 4, July 2019

The changing picture of neonatal abstinence syndrome: ‘new drugs on the block’

Rachel Toone, Kathryn Johnson, Cath Harrison


Neonatal abstinence syndrome (NAS) is usually associated with maternal opioid use but the pattern of drug use is changing, with many affected infants now having been exposed to new psychoactive substances in utero. This article will focus on emerging recreational substances, particularly synthetic cannabinoids, the challenges faced in the management of NAS in these cases, and the potential long-term consequences.

Toone R., Johnson K., Harrison C. The changing picture of neonatal abstinence syndrome: ‘new drugs on the block’. Infant 2019;15(4): 138-40.
Abbreviated: Please subscribe and log in to see the full article.

 
© Copyright of Stansted News Limited 2019. Terms & Conditions of reading. Privacy policy